FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy
Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of Duchenne Muscular Dystrophy.
Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of Duchenne Muscular Dystrophy.
Two gene therapies approved by the FDA last week for the treatment of sickle cell disease will have multimillion dollar price tags for patients (and insurers), according to Reuters.
Individuals living with severe sickle cell disease (SCD) are highly interested in new, potentially curative gene therapy treatments and are willing to accept associated risks for a chance at a cure, according to a study published in Blood Advances.
The phase 2 clinical trial is expected to be a multi-center, randomized, double-blind, placebo-controlled study assessing the drug’s safety and effectiveness in treating approximately 90 pulmonary sarcoidosis patients.
Read MoreThe US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
Read MoreMerck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreMyasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in skeletal muscle, including muscles needed for respiration.
Read MoreA treatment for the rare cancer-like lung disease found in women of childbearing age may have been discovered by University of Cincinnati researchers.
Read MoreIn this on-demand webinar from RT Magazine, a panel of respiratory care experts discussed effective and successful strategies for treating bronchiectasis.
Read MoreThe tool, which has been granted FDA Breakthrough Device Designation, is being developed to serve as adjunct in assessment of ILD, potentially avoiding expensive, invasive surgical testing.
Read MoreThe VA is studying the chronic symptoms of Gulf War Illness, a disease that includes respiratory dysfunction and affects about one-third of US veterans who served in the Persian Gulf.
Read MoreBronchiectasis is linked to several underlying causative agents and involves permanent airway damage, dilated bronchi, retained secretions, chronic infection, and persistent inflammation. But respiratory therapists have several airway clearance therapy options to treat the disease.
Read MoreChronic rhinitis patients treated with the Neuromark System demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months, according to new data.
Read MoreThe expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read MoreNeurent Medical’s Neuromark Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited US markets, the company reports.
Read More